Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

Open access
Gerlag, Danielle M, Safy, Mary, Maijer, Karen I, Tang, Man Wai, Tas, Sander W, Starmans-Kool, Mirian J F, van Tubergen, Astrid, Janssen, Matthijs, de Hair, Maria, Hansson, Monika, de Vries, Niek, Zwinderman, Aeilko H, Tak, Paul P · 2019 · Annals of the Rheumatic Diseases

Abstract

OBJECTIVES: We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development. METHODS: Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo. RESULTS: Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12 months compared with placebo treatment at the point when 25% of the subjects had developed arthritis (p<0.0001). Erythrocyte sedimentation rate and the presence of anti-citrullinated α-enolase peptide 1 at baseline were significant predictors of arthritis development. CONCLUSIONS: A single infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2017-212763

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 28 references

Cited by

See all 295

Metadata

Authors
Gerlag, D. M., Safy, M., Maijer, K. I., Tang, M. W., Tas, S. W., Starmans-Kool, M. J. F., van Tubergen, A., Janssen, M., de Hair, M., Hansson, M., de Vries, N., Zwinderman, A. H., & Tak, P. P.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2019-02
Volume
78
Issue
2
Pages
179-185
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2903122430
Cited by
295
References
28
FWCI
19.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212763
The paper
Gerlag, D. M., Safy, M., Maijer, K. I., Tang, M. W., Tas, S. W., Starmans-Kool, M. J. F., van Tubergen, A., Janssen, M., de Hair, M., Hansson, M., de Vries, N., Zwinderman, A. H., & Tak, P. P. (2019). Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.